The US research-based pharma industry is continuing to call for broad reforms to ensure the sustainability of Japan’s healthcare ecosystem, which it sees as essential to rebuilding the country’s attractiveness as a location for innovation and new drug development.
Ricks Renews PhRMA Call For Comprehensive Japan Policy Dialog
'Transparency And Predictability' Needed
US research-based group again calls for a comprehensive dialog with all healthcare system stakeholders in Japan to address what it sees as "harmful" policies that have reduced the country's support for innovation and attractiveness as a market for drug development amid the rapid rise of some regional neighbors.
